Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPINE trial of intra-arterial lutetium-177 PSMA-I&T for recurrent or progressive adult diffuse glioma
NL-OMON60267Phase 2Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Dec 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2 trial of lutetium Lu 177 PSMA I&T in diffuse midline glioma (DMG), astrocytoma, Oligodendroglioma (OG) and 1 more, sponsored by Erasmus MC. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
lutetium Lu 177 PSMA I&T
03
Conditions
diffuse midline glioma (DMG)astrocytomaOligodendroglioma (OG)glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON60267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60267.